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Abstract 
Cancer therapy is largely dependent on general treatment 
guidelines, and patients undergoing chemotherapy often 
experience treatment failure with standard drugs. The 
development of individualized drug therapy through phar-
macogenomics has the potential to enhance chemotherapy 
regimen selection and improve patient outcomes. Antineo-
plastic agents such as cetuximab and trastuzumab are effec-
tive in treating cancers possessing specific genetic biomarker 
characteristics. Patients need to undergo genetic testing 
before these agents are administered to ensure appropriate 
use. Cetuximab has been shown to improve outcomes in 
metastatic colorectal cancers and head and neck squamous 
cell carcinomas positive for EGFR. Trastuzumab has shown 
benefit in human epidermal growth factor receptor 2 (HERZ) 
overexpressing cancers affecting the breast tissue and 
gastrointestinal tract. High costs associated with the devel-
opment of targeted drugs and a lack of clinical studies 
exploring the effects genetic variations can have on drug 
therapy limit implementation of pharmacogenomics into 
routine practice. As drug therapy experts, pharmacists need 
to be aware of advances in the field of pharmacogenomics 
and facilitate the use of this new class of personalized drugs. 
Introduction 
Patients diagnosed with cancer are treated on the basis of 
standard drug therapy and dosing guidelines. 1 Many factors, 
such as body weight, age and medical history, may also be 
considered in choosing a medication regimen. Despite these 
considerations, a patient's response to drug therapy cannot 
be predicted using current methods and practice guidelines. 
This could translate into repeat visits to the oncologist for 
medication changes and additional rounds of chemotherapy, 
with an increased risk of incapacitating side effects. For 
patients diagnosed with cancer, therapeutic failure can be 
devastating and there is often little time for a trial and error 
approach. The development of individualized therapy 
through pharmacogenomics has the potential to enhance 
chemotherapy regimen selection and improve patient 
outcomes. Targeted antineoplastic medications, such as 
cetuximab and trastuzumab, can be extremely beneficial in 
oncology patients with specific genetic variant biomarkers, 
but also have the potential to cause life-threatening adverse 
effects. In order to reduce patients' exposure to dangerous 
medications in the absence of a potential benefit, genetic 
testing is required prior to administration of these drugs to 
identify those patients who will most likely exhibit a positive 
response. Despite the obvious benefits of pharmacogenom-
ics, barriers exist in both research and integration into 
practice. Pharmacists are in a key position to advocate for 
individualized drug therapy and to inform other health care 
providers on the use and benefits of pharmacogenomics. 
Figure 1. Average chemotherapeutic drug failure.z 
PERCENTAGE OF THE PATIENT POPULATION FOR WHICH 
A PARTICULAR DRUG IS INEFFECTIVE, ON AVERAGE 
CANCER DRUGS 75% 
Cetuximab 
Cetuximab (Erbitux®) is a recombinant chimeric IgG1 anti-
body that binds to the extracellular domain of epidermal 
growth factor receptor (EGFR)-1. EGFR is responsible for the 
growth and differentiation of epithelial cells. When epider-
mal growth factor (EGF) binds to the extracellular domain of 
EGFR, receptor dimerization occurs and intracellular protein 
tyrosine kinases are activated. Following kinase activation, 
various signaling pathways are stimulated, such as RAS-RAF-
mitogen-activated protein kinase (MAPK) and phosphoinosi-
tide 3-kinase (PI3K-AKT) pathways. Once activated, these 
pathways' signals can regulate cell proliferation, differentia-
tion and survival. Cetuximab binds to the extracellular 
domain of EGFR with high affinity and competitively inhibits 
ligands from binding to the receptor.3 This leads to inhibition 
of phosphorylation of intracellular protein tyrosine kinases 
and prevents the activation of the downstream signaling 
pathways, resulting in the inhibition of cell growth and pro-
liferation, ultimately inhibiting tumor growth (Figure 2). 
Cetuximab was the first EGFR inhibitor approved for the 
treatment of metastatic colorectal cancer (mCRC). It is used 
as monotherapy in the treatment of EGFR-positive mCRC in 
patients who cannot tolerate traditional irinotecan-based 
therapy or in combination with irinotecan in patients who 
did not respond to oxaliplatin, irinotecan and 5-fluorouracil 
(5-FU). Traditional therapy in the treatment of mCRC in-
cludes a combination of 5-FU or capecitabine, with either 
oxaliplatin or irinotecan. Using cetuximab in combination 
with 5-FU and irinotecan or oxaliplatin has been shown to 
improve outcomes in the first- and second-line setting of 
mCRC. 
Cetuximab can improve overall survival when used in combi-
nation with radiation therapy in the treatment of locally or 
regionally advanced head and neck squamous cell carcinoma 
(HNSCC). It is used as a monotherapy agent in patients with 
metastatic or recurrent HNSCC. These patients do not typi-
cally respond to platinum-based chemotherapy. Cetuximab 
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has also been shown to improve survival when used in com-
bination with cisplatin-based chemotherapy, as compared to 
cisplatin alone. 4 
KRAS Mutation 
RAS proteins are involved in the EGFR signaling pathways 
that ultimately result in cell proliferation, differentiation and 
survival. The three human RAS genes-HRAS, KRAS and 
NRAS -- are involved in the pathogenesis of tumors through 
cell proliferation, angiogenesis and anti-apoptosis pathways.3 
RAS proteins are small GTP-GDP-binding proteins which act 
as self-inactivating signal transducers cycling from the GDP-
to GTP-bound states as a result of EGF binding to the EGFR. 
These oncogenic RAS proteins have reduced GTPase activity 
which results in an abundance of RAS proteins in the GTP-
bound active state due to an inability to cycle back to the GDP 
-bound inactive state. This results in further activation of the 
downstream signaling pathways promoting cancer cell 
proliferation, angiogenesis and resistance to apoptosis. 
Mutations in the coding region of the KRAS gene lead to a 
constitutively active gene, which is not dependent on 
upstream activation of the EGFR. Cetuximab prevents the 
downstream cell signaling pathways from occurring by 
blocking EGF from binding the EGFR. Because EGFR activa-
tion results in KRAS protein activation, mutations in the cod-
ing region of the KRAS gene lead to a constitutively active 
KRAS gene. This mutated KRAS gene is not dependent on the 
upstream signaling pathways.s 
Figure 2: Cetuximab and its effects on the EGF pathway.3 
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A randomized trial completed by the National Cancer Insti-
tute of Canada Clinical Trials Group with the Australasian 
Gastro-Intestinal Trials Group demonstrated that patients 
harboring KRAS mutations had reduced response rates to 
cetuximab therapy, compared to patients with wild-type 
KRAS genes. The cetuximab therapy group revealed that pa-
tients with wild-type KRAS tumors had a response rate to 
cetuximab that was 12.8 percent, compared to a 1.2 percent 
response rate in patients with a mutated KRAS gene.6 
Mutations of the KRAS gene occur as point mutations in 
codons 12 and 13 of exon 2. These mutations occur early in 
the development of mCRC carcinogenesis. Thirty-five to 40 
percent of colorectal cancer (CRC) cases have KRAS muta-
tions. KRAS mutation incidence is identical among all stages 
of CRC. Identification of KRAS mutations are considered to be 
a predictor of testing resistance to anti-EGFR monoclonal 
antibody therapy.3 The American Society of Clinical Oncology 
Provisional Clinical Option has issued a recommendation 
that all patients with mCRC that are candidates for anti-EGFR 
monoclonal antibody therapy must have tumor cells tested 
for the presence of KRAS mutations prior to initiating drug 
therapy.7 If the results show a KRAS mutation in codons 12 
or 13, patients should not receive anti-EGFR monoclonal an-
tibody therapy due to predicted resistance. 
Testing for KRAS Mutations 
KRAS mutations are detected by the DxS-K-ras test kit. It can 
detect seven somatic mutations on codons 12 and 13 on the 
KRAS gene. The kit has seven primers that are specific in de-
tecting the most common mutations in codons 12 and 13. 
These primers are complementary to the KRAS gene immedi-
ately adjacent to the mutation sites. Each primer has a 
unique sequence at the 3' end specific for the mutation. Dur-
ing polymerase chain reaction (PCR) amplification, the prim-
ers attach to the template strand and only the primer with 
the complementary nucleotide at the 3' end will extend the 
mutated target DNA.S Taq DNA polymerase is used in this 
test because it is very effective in distinguishing the differ-
ences between a match and mismatch nucleotide at the 3' 
end of a PCR primer. If the primer completely matches, am-
plification will occur with full efficiency; in the case of a 3' 
nucleotide base pair mismatch, amplification is reduced. This 
means only the mutated strand that matches the primer will 
be able to be extended. Amplification is detected using Scor-
pions, which are bifunctional molecules with a PCR primer 
covalently linked to a fluorescent probe. The fluorophore in 
the probe reacts with a quencher in the probe which results 
in a reduction in fluorescence. During the PCR amplification 
the probe binds to an amplicon, causing the fluorephore and 
quencher in the probe to become separated and increasing 
the amount of fluorescence observed in the reaction tube. 
Mutated KRAS genes will demonstrate a greater fluorescence 
reaction than wild-type KRAS genes because the mutated 
genes have a greater amount of amplification during PCR 
than the wild-type KRAS gene.a 
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Alternative Treatment Options for Patients with KRAS 
Mutations 
The KRAS oncogene is the most commonly mutated gene in 
different human cancers and, due to its constitutive activity, 
it has the ability to bypass EGFR signaling cascade, therefore 
conferring resistance to anti-EGFR therapies such as cetuxi-
mab. Since patients with mCRC harboring KRAS mutations do 
not show a clinical response to cetuximab, they will have to 
consider other treatment options in order to control and 
treat their cancer. Some of these options include therapy that 
targets molecules downstream of RAS proteins such as RAF 
inhibitors. RAF is an effector molecule downstream of RAS in 
the ERK signaling pathway, making it a potential target for 
treating KRAS mutated tumors. Sorafenib, one of the first 
RAF inhibitors, has multikinase inhibitory actions against 
CRAF, BRAF, V600E mutant form of BRAF, vascular endothe-
lial growth factor receptor (VEGFR) and platelet derived 
growth-factor receptor (PDGFR). Sorafenib has been ap-
proved for the treatment of advanced renal cell carcinoma 
and hepatocellular carcinoma; however it is a relatively weak 
RAF inhibitor. Another option is using a combination of tar-
geted agents. Since RAS activation results in activation of 
various branching pathways, blocking one downstream tar-
get of RAS will theoretically not be enough to inhibit tumor 
growth. Dual-targeted or multi-targeted therapy may be 
more efficient in eliminating cancer cells and fighting drug 
resistance in those patients with KRAS mutations.3 
Trastuzumab 
Trastuzumab (Herceptin®) is a human epidermal growth 
factor receptor 2 (HER2) antagonist. It is indicated as a treat-
ment option in HER2 overexpressing cancers such as breast 
cancer in combination with doxorubicin, cyclophosphamide 
and paclitaxel or docetaxel; metastatic breast cancer as an 
adjuvant treatment with paclitaxel or used alone; and metas-
tatic gastric or gastroesophageal junction adenocarcinoma in 
conjunction with cisplatin, capecitabine or 5-FU.9 
Epidermal growth factor receptors (HER) dimerize upon 
ligand binding, thereby activating the receptor's tyrosine 
kinase activity. There are four types of HER proteins: HER1, 
HER2, HER3 and HER4. HER2 has no endogenous epidermal 
growth factor ligand, but has been determined to be the most 
preferential binding partner for dimerization with HERl, 
HER3 and HER4 and therefore acts primarily as a co-
receptor.10 These heterodimeric receptors have altered phos-
phorylation sites and cause modified activity. The HER2 het-
erodimers decrease the internalization of the receptor 
thereby amplifying and diversifying the altered signaling 
pathways. These signals ultimately lead to the formation of 
cancer through increased cellular proliferation and, poten-
tially, metastasis of these cancers by increasing the cellular 
migration. It has been observed that HER2 is immunogenic, 
as many cancer patients express cytotoxic T-lymphocytes 
(CTL) which target HER2.11 Trastuzumab inhibits this cellu-
lar proliferation and migration by binding to HER2 and in-
ducing antibody dependent cellular cytotoxicity (ADCC). It 
also causes an upregulation of the MHC-class 1 receptors 
containing the HER2 epitope in overexpressing cancer cells.11 
Trastuzumab is only efficacious in HER2 overexpressing can-
cers, which is why genetic testing must be performed before 
it can be prescribed. The most recent indication for this 
medication is in esophageal adenocarcinoma (EAC). Two 
different EAC cell lines, OEl 9 and OE33, both overexpress 
HER2. Researchers compared trastuzumab efficacy in these 
cell lines and a non-HER2 overexpressing cell line. Both the 
OEl 9 and OE33 cell lines had inhibited proliferation when 
treated with trastuzumab, while the non-HER2 overexpress-
ing cell line had no alteration in cellular growth when treated 
with trastuzumab. Levels of interferon-y (INF-y) produced by 
the OE33 cell line were significantly greater when treated 
with trastuzumab resulting in an increased cytotoxicity to 
the cell line. The OEl 9 cell line did not initially have the 
increased cytotoxicity associated with trastuzumab admini-
stration, owing to a deficiency of the TAP-2 protein, an anti-
gen peptide transporter. The TAP-2 protein is required for 
proper antigen processing by the MHC-class 1 molecules. 
However, when treated with INF-y, an upregulator for the 
TAP-2 protein and then treated with trastuzumab, the OEl 9 
cell line was also sensitized to cytotoxicity by CTLs through a 
MHC-class 1 mediated process.11 
The HER2 proto-oncogene is found on the long arm of 
chromosome 17. Determination of HER2 protein and gene 
overexpression is performed through immunohistochemisty 
(IHC) and in situ hybridization, either fluorescence (FISH) or 
chromogenic (CISH), respectively.12 IHC determines a posi-
tive or negative result for HER2 overexpression through the 
percentage of membrane staining that occurs; if over 30 per-
cent of the cells in the sample have complete membrane 
staining, a +3 or positive score is assigned.13 A FISH result is 
determined by the ratio of the number HER2 signals to the 
number of chromosome 17 signals; the result is considered 
positive for HER2 overexpression if the ratio is greater than 
6 to 1.13 However, the American Society of Clinical Oncology 
(ASCO) reports that approximately 20 percent of all testing 
may be inaccurate. 
The limitations to determining HERZ overexpression in can-
cer are due to a variety of factors. The IHC scoring interpreta-
tion can be highly variable among different laboratories. In 
order to minimize this subjectivity, recent studies have used 
both IHC and FISH to properly determine HER2 expression. 
In a 2011 study all +3 IHC results also had HER2 amplifica-
tion.12 The limitation of the FISH ratio is due to the potential 
of chromosome 17 variations in the centromere. The centro-
mere can exhibit polysomy, having too many copies of the 
centromere or monosomy, having only one copy of the cen-
tromere and these alterations are thought to contribute to 
the inaccuracy of testing.14 This study demonstrated that 
artificial skewing due to an altered centromere caused false 
positive or false negative results. In the case of monosomy, 
positive results should be considered with caution as the 
decreased centromere number can produce an overexagger-
ated HER2/CEP17 ratio. In cases of polysomy, negative re-
sults should be closely examined as a lower than expected 
ratio may occur if the CEPl 7 has many more than two cen-
tromeres.14 These factors must therefore be taken into care-
ful consideration when conducting the mandatory genetic 
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testing prior to prescribing trastuzumab. 
Motivations and Liinitations to Pharmacogenoinic Drug 
Development 
Although pharmacogenetic testing has not become common-
place in all pharmaceutical settings, it is becoming increas-
ingly prevalent before prescribing and to determine dosing 
for many oncology treatments. Many different types of can-
cer can now be identified based upon the specific genetic 
factors present. Cancer treatments are now being tailored to 
target these specific mutations, allowing these treatments to 
be more specific and efficacious. All chemotherapeutics have 
the potential for life-threatening adverse effects and should 
therefore not be prescribed unless the potential benefits out-
weigh the risks, a determination which cannot be conclu-
sively made for some drugs without the use of genetic test-
ing. 
The limitation to this testing and development of genetically 
targeted drugs lies within the fact that the current costs to 
develop these medications do not cover the potential finan-
cial gains from these developments. Although the financial 
gains may not meet the costs of development, the quality of 
life (QOL) improvements gained by patients from these 
medications justify continued research. A 2008 study in Swe-
den demonstrated that the costs of FISH testing and concur-
rent treatment with trastuzumab for positive results (cost 
approximately $63,000) provided a gain of almost 1.5 quality 
adjusted life years (QAL Y). The average costs of these treat-
ments were below the typical willingness to pay threshold 
and therefore this treatment regimen is superior to chemo-
therapy without FISH testing, which provided a lower QALY 
improvement.is Another limitation to the implementation of 
more frequent genetic testing is the lack of pharmaceutical 
studies currently conducted on the effects of genetic varia-
tion on drug metabolism and overall effect. This kind of re-
search would allow for the research and development of 
more targeted medications and could also potentially de-
crease the frequency of adverse events and toxicity by ensur-
ing chemotherapeutics or other drug agents are only used 
within populations which will see benefits outweighing the 
risks associated with the drug treatment course. 
Conclusion 
The benefits of pharmacogenomics have already been ob-
served in chemotherapy through the cases of cetuximab and 
trastuzumab. Both agents have demonstrated effectiveness 
in oncology patients possessing specific genetic biomarker 
characteristics. Cetuximab has been shown to improve out-
comes in metastatic colorectal cancers as well as head and 
neck squamous cell carcinomas positive for EGFR. Trastuzu-
mab has shown benefit in HER2 overexpressing cancers af-
fecting the breast tissue and gastrointestinal tract. Utilizing 
genetic testing is essential for appropriate use of these drugs. 
Personalized treatments can greatly improve chances of sur-
vival through earlier administration of effective drug therapy 
and decreased exposure to toxic antineoplastic agents 
unlikely to provide benefit to the patient.16 Developing clini-
cal pharmacy services in pharmacogenomics is one possible 
step in implementing the routine use of personalized drug 
therapy. Pharmacy services could include providing guide-
lines to physicians regarding genetic testing, initial drug 
selection and dosage adjustments.17 Although pharmacoge-
nomics is still in the early stages in practice, pharmacists can 
play a vital role in the implementation and use of pharmaco-
genomics in therapeutic decision making. 
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